Table 1 |
|||
|
Patient baseline characteristics |
|||
| Losartan (n = 20) |
Telmisartan (n = 20) |
P value |
|
|
|
|||
| Mean ± SD age (years) |
56.2 ± 11.0 |
55.3 ± 12.4 |
NS |
| Males/females |
11/9 |
12/8 |
|
| Office blood pressure (mmHg) |
|||
| Mean ± SD SBP |
149.7 ± 9.0 |
151.3 ± 7.1 |
|
| Mean ± SD DBP |
91.2 ± 7.4 |
89.8 ± 8.7 |
|
| 24-hour mean blood pressure (mmHg) |
|||
| Mean ± SD SBP |
142.8 ± 12.0 |
143.6 ± 14.0 |
NS |
| Mean ± SD DBP |
88.8 ± 10.2 |
88.3 ± 9.5 |
NS |
| Mean ± SD body mass index (kg/m2) |
32.1 ± 7.2 |
34.5 ± 6.3 |
NS |
| Impaired glucose tolerance (n) |
19 |
17 |
NS |
| Type 2 diabetics (n) |
1 |
3 |
NS |
| Metabolic syndrome components (n)a |
|||
| 3 |
11 |
10 |
NS |
| 4 |
7 |
8 |
NS |
| 5 |
2 |
2 |
NS |
| Total cholesterol (mg/dl) |
212.6 ± 45.8 |
209.6 ± 50.8 |
NS |
| Low-density lipoprotein cholesterol (mg/dl) |
134 ± 44 |
138 ± 34 |
NS |
| High-density lipoprotein cholesterol (mg/dl) |
51.2 ± 11 |
56.3 ± 17 |
NS |
| Triglycerides (mg/dl) |
221 ± 32 |
210 ± 23 |
NS |
|
a Based on World Health Organization criteria [1]. | |||
Vitale et al. Cardiovascular Diabetology 2005 4:6 doi:10.1186/1475-2840-4-6 |
|||
